{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:44:21Z","timestamp":1740109461146,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00259-017-3841-y","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T11:45:59Z","timestamp":1507808759000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer\u2019s question"],"prefix":"10.1007","volume":"45","author":[{"given":"A.","family":"Gallamini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-3330","authenticated-orcid":false,"given":"M.","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"3841_CR1","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2008.16.1711","volume":"26","author":"LE Dodd","year":"2008","unstructured":"Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791\u20136.","journal-title":"J Clin Oncol"},{"key":"3841_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1634\/theoncologist.2009-0261","volume":"15","author":"O Amit","year":"2010","unstructured":"Amit O, Bushnell W, Dodd L, et al. Blinded Indipendent central review of progression-free survival endpoint. Oncologist. 2010;15:492\u20135.","journal-title":"Oncologist"},{"issue":"27","key":"3841_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3841_CR4","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphoma working group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"3841_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:1598\u2013607.","journal-title":"N Engl J Med"},{"key":"3841_CR6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V126.23.578.578","volume":"126","author":"DJ Straus","year":"2015","unstructured":"Straus DJ, Pitcher B, Kostakoglu L, et al. Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy\/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB\/Alliance 50604). Blood. 2015;126:578. [abstr.]","journal-title":"Blood"},{"issue":"16","key":"3841_CR7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment of stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35(16):1786\u201394.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1 June 2","key":"3841_CR8","first-page":"163","volume":"33","author":"A Gallamini","year":"2015","unstructured":"Gallamini A, Rossi A, Patti C, et al. Interim PET-adapted chemotherapy in advanced Hodgkin Lymphoma (HL). Results of the second interim analysis of the Italian GITIL\/FIL HD 0607 trial. Hematol Oncol. 2015;33(Suppl. 1 June 2015):163. Abstract 118","journal-title":"Hematol Oncol"},{"key":"3841_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med"},{"key":"3841_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Shoder H, et al. US Intergroup trial of response adapted for stage III to IV Hodgkin Lymphoma using early interim Fluorodeoxyglucose -Positron Emission Tomography imaging: Southwest Oncology Group S 0816. J Clin Oncol. 2016;34:2020\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3841_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Havenkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced-stage Hodgkin\u2019s lymphoma treated BEACOPP ESCALATED alone or in combination with Rituxinab (HD18): an open-label, international randomized phase 3study by the German Hodgkin Study Group. Lancet Oncol. 2017;18(4):454\u201363.","journal-title":"Lancet Oncol"},{"key":"3841_CR12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","volume":"126","author":"O Casasnovas","year":"2015","unstructured":"Casasnovas O, Brice P, Bouabdallah R, et al. Randomized phase III trial comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin Lymphoma: interim analysis of the AHL2011 Lysa Study. Blood. 2015;126:577. [abstr.]","journal-title":"Blood"},{"issue":"10","key":"3841_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","volume":"37","author":"SF Barrington","year":"2010","unstructured":"Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin Lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3841_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","volume":"127","author":"SF Barrington","year":"2016","unstructured":"Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531\u20138.","journal-title":"Blood"},{"key":"3841_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.112.110890","volume":"54","author":"A Biggi","year":"2013","unstructured":"Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683\u201390.","journal-title":"J Nucl Med"},{"key":"3841_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient for agreement for nominal scales. Educ Psychol Meas. 1960;20:37\u201346.","journal-title":"Educ Psychol Meas"},{"key":"3841_CR17","doi-asserted-by":"crossref","unstructured":"Hayes AS, Krippendorf K. Answering the call for a standard reliability measure for coding data. Commun Method Meas. 2007;1:77\u201389.","DOI":"10.1080\/19312450709336664"},{"key":"3841_CR18","doi-asserted-by":"crossref","unstructured":"Kobe C, Kuhnert G, Kahraman D, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography\/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776\u201381.","DOI":"10.1200\/JCO.2013.53.2507"},{"key":"3841_CR19","doi-asserted-by":"crossref","unstructured":"Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27:2739\u201341.","DOI":"10.1200\/JCO.2009.22.4089"},{"key":"3841_CR20","doi-asserted-by":"crossref","unstructured":"Chauvie S, Biggi A, Stancu A et al: WIDEN: a tool for medical image management in clinical trials. Clinical Trial 2014;0:1\u20137.","DOI":"10.1177\/1740774514525690"},{"key":"3841_CR21","doi-asserted-by":"publisher","unstructured":"Ceriani L, Barrington S, Biggi A, et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. Hematol Oncol. 2016. https:\/\/doi.org\/10.1002\/hon.2339 .","DOI":"10.1002\/hon.2339"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3841-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T18:02:23Z","timestamp":1603130543000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3841-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3841"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3841-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2017,10,12]]},"assertion":[{"value":"21 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards [<!--CitationRef removed-->14]"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}]}}